Achieve Life Sciences Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.82 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $8.09Price as of 30 Sep 2026 Data confidenceNot applicable Market Cap $832.5M Enterprise Value $792M Shares Outstanding 102.9M diluted Next Earnings Date9 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Achieve Life Sciences is a late-stage specialty pharmaceutical company focused on developing cytisinicline for nicotine dependence (smoking and vaping cessation). While cytisinicline has demonstrated robust efficacy and safety across Phase 3 trials (ORCA-2 and ORCA-3), the near-term outlook is tempered by a regulatory delay. Due to an Official Action Indicated (OAI) classification at its prior contract manufacturer, the company expects to receive a Complete Response Letter (CRL) from the FDA on or before its June 20, 2026 PDUFA date. Achieve has proactively pivoted its manufacturing to U.S.-based Adare Pharma Solutions, successfully completing technology transfer and an initial engineering batch. A massive private placement of up to $354 million (including $180 million upfront) secures the company's financial runway through the anticipated Q4 2026 NDA resubmission and planned 1H 2027 commercial launch. Given the delayed timeline and execution risks associated with the manufacturing transition, a Hold recommendation is warranted until the NDA is successfully resubmitted and accepted by the FDA. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$9.00 Mean target$13.80 High · most bullish analyst$21.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The FDA's CRL raises unexpected clinical or safety concerns, or the technology transfer to Adare encounters validation delays, pushing the NDA resubmission into 2027. Subsequent FDA inspections of Adare's facility reveal cGMP observations, further delaying approval. Cash burn increases, and the company is forced to seek dilutive financing if milestone warrants cannot be exercised, severely depressing the stock price. Base CaseCentral scenario The FDA issues a CRL on or before June 20, 2026, solely due to the prior manufacturer's cGMP issues. Achieve successfully resubmits the cytisinicline NDA in Q4 2026 naming Adare Pharma Solutions as the primary manufacturer. The FDA accepts the resubmission, leading to approval and a successful commercial launch in 1H 2027. The company initiates and advances the ORCA-V2 Phase 3 trial for vaping cessation, positioning cytisinicline as a highly differentiated therapy in a multi-billion dollar market. Bull CaseUpside scenario Achieve Life Sciences' bull case centers on cytisinicline, a selective plant-derived partial agonist at nicotinic acetylcholine receptors designed for nicotine dependence. The clinical package is highly robust, backed by statistically significant and clinically meaningful continuous abstinence rates in two Phase 3 smoking-cessation trials (ORCA-2 and ORCA-3). Following a Complete Response Letter (CRL) from the FDA primarily addressing manufacturing and labeling issues rather than safety or efficacy, Achieve partnered with Adare Pharma Solutions (a US-based CDMO) to resolve cGMP requirements and is targeting an NDA resubmission in Q4 2026, positioning cytisinicline for a potential commercial launch in 1H 2027. Furthermore, cytisinicline offers significant pipeline optionality as a potential first-in-class prescription treatment for the massive, underserved e-cigarette (vaping) cessation market, supported by positive Phase 2 data and an upcoming Phase 3 program under an FDA Expedited Review (CNPV). The company's commercial strategy is highly capital-efficient, focusing on digital outreach, payer coverage, and high-yield prescribers rather than a costly legacy field force, and is fully funded into 2027 following a major $168.6 million net private placement in April 2026. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |